Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection
Status:
Withdrawn
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
A prospective study to assess the efficacy and safety of fidaxomicin in Solid Organ
Transplant (SOT) recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with
a first-episode of Clostridium difficile infection (CDI).